vs
PUMA BIOTECHNOLOGY, INC.（PBYI）与SOLENO THERAPEUTICS INC（SLNO）财务数据对比。点击上方公司名可切换其他公司
PUMA BIOTECHNOLOGY, INC.的季度营收约是SOLENO THERAPEUTICS INC的1.1倍（$75.5M vs $66.0M），SOLENO THERAPEUTICS INC自由现金流更多（$43.5M vs $14.4M）
彪马生物技术是一家公开上市的生物制药企业，总部位于美国加利福尼亚州洛杉矶，专注于创新药物研发相关业务，在生物制药领域开展研发与商业化运营。
索雷诺治疗是一家临床阶段生物制药企业，专注于开发针对罕见内分泌、代谢及神经发育疾病的创新疗法，核心在研药物用于治疗普拉德-威利综合征，服务覆盖北美、欧盟等地区的罕见病患者群体。
PBYI vs SLNO — 直观对比
营收规模更大
PBYI
是对方的1.1倍
$66.0M
自由现金流更多
SLNO
多$29.1M
$14.4M
损益表 — Q4 FY2025 vs Q3 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $75.5M | $66.0M |
| 净利润 | — | $26.0M |
| 毛利率 | 69.3% | 98.3% |
| 营业利润率 | 22.7% | 33.5% |
| 净利率 | — | 39.4% |
| 营收同比 | 27.7% | — |
| 净利润同比 | — | 134.0% |
| 每股收益（稀释后） | $0.26 | $0.47 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收PBYISLNO
| Q4 25 | $75.5M | — | ||
| Q3 25 | $54.5M | $66.0M | ||
| Q2 25 | $52.4M | $32.7M | ||
| Q1 25 | $46.0M | — | ||
| Q4 24 | $59.1M | — | ||
| Q3 24 | $80.5M | — | ||
| Q2 24 | $47.1M | — | ||
| Q1 24 | $43.8M | — |
净利润PBYISLNO
| Q4 25 | — | — | ||
| Q3 25 | $8.8M | $26.0M | ||
| Q2 25 | $5.9M | $-4.7M | ||
| Q1 25 | $3.0M | — | ||
| Q4 24 | — | — | ||
| Q3 24 | $20.3M | — | ||
| Q2 24 | $-4.5M | — | ||
| Q1 24 | $-4.8M | — |
毛利率PBYISLNO
| Q4 25 | 69.3% | — | ||
| Q3 25 | 77.7% | 98.3% | ||
| Q2 25 | 76.5% | 97.9% | ||
| Q1 25 | 77.1% | — | ||
| Q4 24 | 76.4% | — | ||
| Q3 24 | 63.9% | — | ||
| Q2 24 | 77.4% | — | ||
| Q1 24 | 75.5% | — |
营业利润率PBYISLNO
| Q4 25 | 22.7% | — | ||
| Q3 25 | 17.6% | 33.5% | ||
| Q2 25 | 12.7% | -20.0% | ||
| Q1 25 | 8.7% | — | ||
| Q4 24 | 22.6% | — | ||
| Q3 24 | 27.4% | — | ||
| Q2 24 | -4.6% | — | ||
| Q1 24 | -5.3% | — |
净利率PBYISLNO
| Q4 25 | — | — | ||
| Q3 25 | 16.2% | 39.4% | ||
| Q2 25 | 11.2% | -14.4% | ||
| Q1 25 | 6.5% | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 25.2% | — | ||
| Q2 24 | -9.6% | — | ||
| Q1 24 | -11.0% | — |
每股收益（稀释后）PBYISLNO
| Q4 25 | $0.26 | — | ||
| Q3 25 | $0.17 | $0.47 | ||
| Q2 25 | $0.12 | $-0.09 | ||
| Q1 25 | $0.06 | — | ||
| Q4 24 | $0.40 | — | ||
| Q3 24 | $0.41 | — | ||
| Q2 24 | $-0.09 | — | ||
| Q1 24 | $-0.10 | — |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $97.5M | $498.9M |
| 总债务越低越好 | $22.7M | — |
| 股东权益账面价值 | $130.3M | $494.8M |
| 总资产 | $216.3M | $599.9M |
| 负债/权益比越低杠杆越低 | 0.17× | — |
8季度趋势，按日历期对齐
现金及短期投资PBYISLNO
| Q4 25 | $97.5M | — | ||
| Q3 25 | $94.4M | $498.9M | ||
| Q2 25 | $96.0M | $286.8M | ||
| Q1 25 | $93.2M | — | ||
| Q4 24 | $101.0M | — | ||
| Q3 24 | $96.7M | — | ||
| Q2 24 | $96.8M | — | ||
| Q1 24 | $107.2M | — |
总债务PBYISLNO
| Q4 25 | $22.7M | — | ||
| Q3 25 | $34.0M | — | ||
| Q2 25 | $45.3M | — | ||
| Q1 25 | $56.7M | — | ||
| Q4 24 | $68.0M | — | ||
| Q3 24 | $79.3M | — | ||
| Q2 24 | $90.7M | — | ||
| Q1 24 | $102.0M | — |
股东权益PBYISLNO
| Q4 25 | $130.3M | — | ||
| Q3 25 | $115.3M | $494.8M | ||
| Q2 25 | $104.7M | $240.1M | ||
| Q1 25 | $97.1M | — | ||
| Q4 24 | $92.1M | — | ||
| Q3 24 | $71.1M | — | ||
| Q2 24 | $48.5M | — | ||
| Q1 24 | $51.0M | — |
总资产PBYISLNO
| Q4 25 | $216.3M | — | ||
| Q3 25 | $202.9M | $599.9M | ||
| Q2 25 | $194.9M | $332.3M | ||
| Q1 25 | $196.2M | — | ||
| Q4 24 | $213.3M | — | ||
| Q3 24 | $220.7M | — | ||
| Q2 24 | $205.0M | — | ||
| Q1 24 | $214.1M | — |
负债/权益比PBYISLNO
| Q4 25 | 0.17× | — | ||
| Q3 25 | 0.30× | — | ||
| Q2 25 | 0.43× | — | ||
| Q1 25 | 0.58× | — | ||
| Q4 24 | 0.74× | — | ||
| Q3 24 | 1.12× | — | ||
| Q2 24 | 1.87× | — | ||
| Q1 24 | 2.00× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $14.4M | $43.5M |
| 自由现金流经营现金流 - 资本支出 | $14.4M | $43.5M |
| 自由现金流率自由现金流/营收 | 19.1% | 65.8% |
| 资本支出强度资本支出/营收 | 0.0% | 0.0% |
| 现金转化率经营现金流/净利润 | — | 1.67× |
| 过去12个月自由现金流最近4个季度 | $41.7M | — |
8季度趋势，按日历期对齐
经营现金流PBYISLNO
| Q4 25 | $14.4M | — | ||
| Q3 25 | $9.7M | $43.5M | ||
| Q2 25 | $14.1M | $-12.6M | ||
| Q1 25 | $3.6M | — | ||
| Q4 24 | $15.6M | — | ||
| Q3 24 | $11.0M | — | ||
| Q2 24 | $1.0M | — | ||
| Q1 24 | $11.2M | — |
自由现金流PBYISLNO
| Q4 25 | $14.4M | — | ||
| Q3 25 | $9.7M | $43.5M | ||
| Q2 25 | $14.1M | $-12.6M | ||
| Q1 25 | $3.6M | — | ||
| Q4 24 | $15.6M | — | ||
| Q3 24 | $11.0M | — | ||
| Q2 24 | $1.0M | — | ||
| Q1 24 | — | — |
自由现金流率PBYISLNO
| Q4 25 | 19.1% | — | ||
| Q3 25 | 17.7% | 65.8% | ||
| Q2 25 | 26.8% | -38.6% | ||
| Q1 25 | 7.7% | — | ||
| Q4 24 | 26.4% | — | ||
| Q3 24 | 13.7% | — | ||
| Q2 24 | 2.1% | — | ||
| Q1 24 | — | — |
资本支出强度PBYISLNO
| Q4 25 | 0.0% | — | ||
| Q3 25 | 0.0% | 0.0% | ||
| Q2 25 | 0.0% | 0.0% | ||
| Q1 25 | 0.1% | — | ||
| Q4 24 | 0.0% | — | ||
| Q3 24 | 0.0% | — | ||
| Q2 24 | 0.0% | — | ||
| Q1 24 | 0.0% | — |
现金转化率PBYISLNO
| Q4 25 | — | — | ||
| Q3 25 | 1.10× | 1.67× | ||
| Q2 25 | 2.41× | — | ||
| Q1 25 | 1.21× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 0.54× | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
